Calcineurin inactivation leads to decreased responsiveness to LPS in macrophages and dendritic cells and protects against LPS-induced toxicity in vivo

Innate Immunity

Volumn 15, Issue 2, 2009, Pages 109-120

  Jennings, Charay ^a   Kusler, Brenda ^b,c   Jones, Patricia P ^c  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^c STANFORD UNIVERSITY   (United States)

Author keywords

Calcineurin; Cell activation; Dendritic cells; Endotoxin shock; FK506; LPS tolerance; Monocytes macrophages

Indexed keywords

CALCINEURIN; CYCLOOXYGENASE 2; CYCLOSPORIN A; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1; INTERLEUKIN 2; LIPOPOLYSACCHARIDE; TACROLIMUS; TRANSCRIPTION FACTOR NFAT; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE MARROW CELL; C57BL 6 MOUSE; CONTROLLED STUDY; CYTOKINE RELEASE; DENDRITIC CELL; FEMALE; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; INNATE IMMUNITY; KNOCKOUT MOUSE; LETHAL DOSE; MACROPHAGE; MOUSE; NONHUMAN; PHARMACOLOGICAL BLOCKING; SURVIVAL RATE;

ANIMALS; CALCINEURIN; CELL SURVIVAL; CELLS, CULTURED; DENDRITIC CELLS; FEEDBACK, BIOCHEMICAL; FEMALE; IMMUNE TOLERANCE; LIPOPOLYSACCHARIDES; MACROPHAGE ACTIVATION; MACROPHAGES, PERITONEAL; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NF-KAPPA B; SHOCK, SEPTIC; SIGNAL TRANSDUCTION; TACROLIMUS;

MUS;

EID: 63349101130     PISSN: 17534259     EISSN: 17534267     Source Type: Journal    
DOI: 10.1177/1753425908100928     Document Type: Article

References (59)

1. Medzhitov RM Toll-like receptors and innate immunity. Nat Rev Immunol 2001; 1: 135-146.
2. Ozinsky A., Underhill DM, Fontenot JD et al. The repertoire for pattern recognition of pathogens by the innate immune system is defined by cooperation between Toll-like receptors. Proc Natl Acad Sci USA 2000; 97: 13766-13771.
3. Uematsu S., Akira S. Toll-like receptors and innate immunity. J Mol Med 2006; 84: 712-725.
4. Roach JC, Smith KD, Strobe KL et al. Transcription factor expression in lipopolysaccharide-activated peripheral-blood-derived mononuclear cells. Proc Natl Acad Sci USA 2007; 104: 16245-16250.
5. Li Q., Verma IM NF-kappaB regulation in the immune system. Nat Rev 2002; 2: 725-734.
6. Proctor RA, Will JA, Burhop KE, Raetz CRH. Protection of mice against lethal endotoxemia by a lipid A precursor. Infect Immun 1986; 52: 905-907.
7. West MA, Heagy W. Endotoxin tolerance: A review. Crit Care Med 2002; 30 (1 Suppl): S64-S73.
8. Sanchez-Cantu L., Rode HN, Christou NV Endotoxin tolerance is associated with reduced secretion of tumor necrosis factor. Arch Surg 1989; 124: 1432-1436.
9. Lepe-Zuniga JL, Klostergaard J. Tolerance to endotoxin in vitro: independent regulation of interleukin-1, tumor necrosis factor and interferon alpha production during in vitro differentiation of human monocytes. Lymphokine Res 1990; 9: 309-319.
10. Mathison JC, Virca GD, Wolfson E., Tobias PS, Glaser K., Ulevitch RJ Adaptation to bacterial lipopolysaccharide controls lipopolysaccharide-induced tumor necrosis factor production in rabbit macrophages. J Clin Invest 1990; 85: 1108-1118.
11. Medvedev AE, Kopydlowski KM, Vogel SN Inhibition of lipopolysaccharide-induced signal transduction in endotoxintolerized mouse macrophages: Dysregulation of cytokine, chemokine, and Toll-like receptor 2 and 4 gene expression. J Immunol 2000; 164: 5564-5574.
12. Dobrovolskaia MA, Medvedev AE, Thomas KE et al. Induction of in vitro reprogramming by Toll-like receptor TLR2 and TLR4 agonists in murine macrophages: Effects of TLR 'homotolerance' and 'heterotolerance' on NF-kappaB signaling pathway components. J Immunol 2003; 170: 508-519.
13. Karp CL, Wysocka M., Ma X. et al. Potent suppression of IL-12 production from monocytes and dendritic cells during endotoxin tolerance. Eur J Immunol 1998; 28: 3128-3136.
14. Munoz C., Carlet J., Fitting C., Misset B., Bleriot JP, Cavaillon JM Dysregulation of in vitro cytokine production by monocytes during sepsis. J Clin Invest 1991; 88: 1747-1754.
15. Cavaillon JM, Adrie C., Fitting C., Adib-Conquy M. Endotoxin tolerance: is there a clinical relevance? J Endotoxin Res 2003; 9: 101-107.
16. Granowitz EV, Porat R., Mier JW et al. Intravenous endotoxin suppresses the cytokine response of peripheral blood mononuclear cells of healthy humans. J Immunol 1993; 151: 1637-1645.
17. Klee CB, Crouch TH, Krinks MH Calcineurin: A calcium- and calmodulin-binding protein of the nervous system. Proc Natl Acad Sci USA 1979; 76: 6270-6273.
18. Shibasaki F., Hallin U., Uchino H. Calcineurin as a multifunctional regulator. J Biochem 2002; 131: 1-15.
19. Rusnak F., Mertz P. Calcineurin: Form and function. Physiol Rev 2000; 80: 1483-1521.
20. Klee CB, Ren H., Wang X. Regulation of the calmodulin-stimulated protein phosphatase, calcineurin. J Biol Chem 1998; 273: 13367-13370.
21. 2+, calcineurin, and NF-AT. Cell 1999; 96: 611-614.
22. Borel JF Comparative study of in vitro and in vivo drug effects on cell mediated toxicity. Immunology 1976; 31: 631-641.
23. Kino T., Hatanaka H., Hashimoto M. et al. FK-506, a novel immunosuppressant isolated from a Streptomyces. I. Fermentation, isolation, and physico-chemical and biological characteristics. J Antibiot (Tokyo) 1987; 40: 1249-1255.
24. Kino T., Hatanaka H., Miyata S. et al. FK-506, a novel immunosuppressant isolated from a Streptomyces. II. Immunosuppressive effect of FK-506 in vitro. J Antibiot (Tokyo) 1987; 40: 1256-1265.
25. Goto T., Kino T., Hatanaka H. et al. Discovery of FK-506, a novel immunosuppressant isolated from Streptomyces tsukubaensis. Transplant Proc 1987; 19: 4-8.
26. Tanaka H., Kuroda A., Marusawa H. et al. Physicochemical properties of FK-506, a novel immunosuppressant isolated from Streptomyces tsukubaensis. Transplant Proc 1987; 19: 11-16.
27. Friedman J., Weissman I. Two cytoplasmic candidates for immunophilin action are revealed by affinity for a new cyclophilin: One in the presence and one in the absence of CsA. Cell 1991; 66: 799-806.
28. Clipstone NA, Crabtree GR Identification of calcineurin as a key signaling enzyme in T-lymphocyte activation. Nature 1992; 357: 695-697.
29. Liu J., Albers MW, Wandless TJ et al. Inhibition of T cell signaling by immunophilin-ligand complexes correlates with loss of calcineurin phosphatase activity. Biochemistry 1992; 31: 3896-3901.
30. O'Keefe SJ, Tamura J., Kincaid RL, Tocci MJ, O'Neill EA FK-506- and CsA-sensitive activation of the interleukin-2 promoter by calcineurin. Nature 1992; 357: 692-694.
31. Winslow MM, Gallo EM, Neilson JR, Crabtree GR The calcineurin phosphatase complex modulates immunogenic B cell responses. Immunity 2006; 24: 141-152.
32. Woo DK, James WD Topical tacrolimus: A review of its uses in dermatology. Dermatitis 2005; 16: 6-21.
33. Tse KC, Lam MF, Tang SC, Tang CS, Chan TM A pilot study on tacrolimus treatment in membranous or quiescent lupus nephritis with proteinuria resistant to angiotensin inhibition or blockade. Lupus 2007; 16: 46-51.
34. Kitahara K., Kawai S. Cyclosporine and tacrolimus for the treatment of rheumatoid arthritis. Curr Opin Rheumatol 2007; 19: 238-245.
35. +-ATPase modulate macrophage effector functions. Proc Natl Acad Sci USA 1999; 96: 6324-6329.
36. Kang YJ, Kusler B., Otsuka M. et al. Calcineurin negatively regulates TLR-mediated activation pathways. J Immunol 2007; 179: 4598-4607.
37. Ferron M., Vacher J. Targeted expression of cre recombinase in macrophages and osteoclasts in transgenic mice. Genesis 2005; 41: 138-145.
38. Nielson JR, Winslow MM, Crabtree AG Essential role of calcineurin B1 in thymocyte positive but not negative selection. Immunity 2004; 20: 255-266.
39. Lutz MB, Kukutsch N., Ogilvie AL et al. An advanced culture method for generating large quantities of highly pure dendritic cells from mouse bone marrow. J Immunol Methods 1999; 223: 77-92.
40. Fan H., Cook JA Molecular mechanisms of endotoxin tolerance. J Endotoxin Res 2004; 10: 71-84.
41. Medvedev AE, Sabroe I., Hasday JD, Vogel SN Tolerance to microbial TLR ligands: Molecular mechanisms and relevance to disease. J Endotoxin Res 2006; 12: 133-150.
42. Freudenberg MA, Galanos C. Induction of tolerance to lipopolysaccharide (LPS)-D-galactosamine lethality by pretreatment with LPS is mediated by macrophages. Infect Immun 1988; 56: 1352-1357.
43. Lee JI, Ganster RW, Geller DA, Burckart GJ, Thomson AW, Lu L. Cyclosporine A inhibits the expression of costimulatory molecules on in vitro-generated dendritic cells: Association with reduced nuclear translocation of nuclear factor kappa B. Transplantation 1999; 68: 1255-1263.
44. Sauma D., Fierro A., Mora JR et al. Cyclosporine preconditions dendritic cells during differentiation and reduces IL-2 and IL-12 production following activation: A potential tolerogenic effect. Transplant Proc 2003; 35: 2515-2517.
45. Angus DC, Linde-Zwirble WT, Lidicker J., Clermont G., Carcillo J., Pinsky MR Epidemiology of severe sepsis in the United States: Analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001; 29: 1303-1310.
46. Watson RS, Carcillo JA Scope and epidemiology of pediatric sepsis. Pediatr Crit Care Med 2005; 6: S3-S5.
47. Venet C., Zeni F., Viallon A. et al. Endotoxaemia in patients with severe sepsis or septic shock. Intensive Care Med 2000; 26: 538-544.
48. Volk HD, Reinke P., Docke WD Clinical aspects: From systemic inflammation to 'immunoparalysis'. Chem Immunol 2000; 74: 162-177.
49. Hubbard WJ, Choudhry M., Schwacha MG et al. Cecal ligation and puncture. Shock 2005; 24 (Suppl 1): 52-57.
50. Remick DG, Ward PA Evaluation of endotoxin models for the study of sepsis. Shock 2005; 24 (Suppl 1): 7-11.
51. Rittirsch D., Hoesel LM, Ward PA The disconnect between animal models of sepsis and human sepsis. J Leukoc Biol 2007; 81: 137-143.
52. Cavaillon JM, Adib-Conquy M. Bench-to-bedside review: Endotoxin tolerance as a model of leukocyte reprogramming in sepsis. Crit Care 2006; 10: 233.
53. Wheeler DS, Lahni PM, Denenberg AG et al. Induction of endotoxin tolerance enhances bacterial clearance and survival in murine polymicrobial sepsis. Shock 2008; 30: 267-273.
54. Singh N. Infectious complications in organ transplant recipients with the use of calcineurin-inhibitor agent-based immunosuppressive regimens. Curr Opin Infect Dis 2005; 18: 342-345.
55. Mason CM, Dobard E., Summer WR, Nelson S. Intraportal lipopolysaccharide suppresses pulmonary antibacterial defense mechanisms. J Infect Dis 1997; 176: 1293-1302.
56. Severn A., Xu D., Doyle J. et al. Pre-exposure of murine macrophages to lipopolysaccharide inhibits the induction of nitric oxide synthase and reduces leishmanicidal activity. Eur J Immunol 1993; 23: 1711-1714.
57. Rayhane N., Fitting C., Lortholary O., Dromer F., Cavaillon JM Administration of endotoxin associated with lipopolysaccharide tolerance protects mice against fungal infection. Infect Immun 2000; 68: 3748-3753.
58. Lehner MD, Ittner J., Bundschuh DS, van Rooijen N., Wendel A., Hartung T. Improved innate immunity of endotoxin-tolerant mice increases resistance to Salmonella enterica serovar Typhimurium infection despite attenuated cytokine response. Infect Immun 2001; 69: 463-471.
59. Foster SL, Hargreaves DC, Medzhitov R. Gene-specific control of inflammation by TLR-induced chromatin modifications. Nature 2007; 447: 972-978.